Ceftazidime therapy of serious bacterial infections.

Ceftazidime, a new broad-spectrum cephalosporin, was administered to 30 patients with serious bacterial infections in a randomized dosing trial with daily doses of 1.5 or 3 g. Both regimens were equally efficacious, with satisfactory clinical responses in 28 instances (93%) and microbiological eradi...

Descripció completa

Dades bibliogràfiques

Publicat a:	Antimicrob Agents Chemother
Autors principals:	Eron, L J, Goldenberg, R I, Park, C H, Poretz, D M
Format:	Artigo
Idioma:	Inglês
Publicat:	American Society for Microbiology (ASM) 1983
Matèries:	Research Article
Accés en línia:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC186028/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/6340601/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.23.2.236
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!